Skip to main content
    PeptideAuthority
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Share:X PostLinkedIn
    Hormonal & Endocrine•Updated 2026-02-01•5 min read

    What Is Calcitonin? Benefits, Research & Safety

    A thyroid hormone involved in calcium regulation, used therapeutically for osteoporosis, Paget's disease, and hypercalcemia.

    Share:X PostLinkedIn
    Also known as:
    Thyrocalcitonin
    CT
    Salmon Calcitonin
    BModerate human evidenceUK: Prescription-only (UK POM)WADA: Low sport risk

    UK summary: UK prescription-only medicine (Miacalcic). Long-term osteoporosis use was restricted in 2013 following EMA review of cancer-risk signals; short-term use for hypercalcaemia and Paget's disease remains appropriate.

    Quick Facts

    Category
    Hormonal & Endocrine
    Half-Life
    Approximately 10-15 minutes (short)
    UK Status
    Available for specific indications; use restricted to short-term treatment.
    EU Status
    Use restricted due to cancer risk concerns; limited indications.

    Overview

    Calcitonin is a 32-amino acid peptide hormone produced by the parafollicular cells (C cells) of the thyroid gland. It plays a role in calcium and bone metabolism, primarily by inhibiting bone resorption through direct effects on osteoclasts. The hormone is released in response to elevated blood calcium levels and acts to lower calcium by inhibiting bone breakdown and promoting calcium excretion by the kidneys. It provides a rapid response to hypercalcemia, complementing the slower-acting parathyroid hormone system. Therapeutically, calcitonin (especially salmon calcitonin, which is more potent than human) has been used for conditions including osteoporosis, Paget's disease of bone, and hypercalcemia of malignancy. It also has analgesic properties for bone pain. The use of calcitonin for osteoporosis has declined with the availability of more effective treatments (bisphosphonates, denosumab, romosozumab). Concerns about potential cancer risk with long-term use have also limited its applications. Calcitonin remains important in diagnostics, with calcitonin levels serving as a tumor marker for medullary thyroid cancer (MTC), which arises from calcitonin-producing C cells.
    Evidence standards summary

    Calcitonin — evidence and risk at a glance

    Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

    01Evidence snapshot

    BModerate human evidenceOverall grade against our evidence grading methodology.

    UK prescription-only medicine (Miacalcic). Long-term osteoporosis use was restricted in 2013 following EMA review of cancer-risk signals; short-term use for hypercalcaemia and Paget's disease remains appropriate.

    02Human evidence grade

    BModerate human evidenceStrength of evidence from published human trials.

    03Preclinical evidence grade

    AStrong human evidenceAnimal-model and in-vitro evidence quality.

    04Regulatory status

    • UK: Available for specific indications; use restricted to short-term treatment.
    • EU: Use restricted due to cancer risk concerns; limited indications.
    • Notes: Calcitonin use has been restricted in many jurisdictions following EMA recommendations in 2013. Long-term use for osteoporosis is no longer recommended. Short-term use for hypercalcemia and Paget's disease remains appropriate.

    05Approved medical uses

    • Hypercalcaemia (acute / cancer-related — Miacalcic IV).
    • Paget's disease of bone (short-term).
    • Acute vertebral fracture pain (nasal calcitonin — limited modern use).

    06Unapproved / promotional claims

    • Calcitonin as first-line long-term osteoporosis treatment.
    • Daily calcitonin nasal spray for healthy adults.

    07Common internet claims

    • Some online sources still promote calcitonin for osteoporosis prevention despite restricted indication.

    08Claim vs evidence

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Best long-term option for osteoporosis”BYesHighCalcitonin is no longer recommended for long-term osteoporosis treatment due to cancer-risk signals; bisphosphonates / denosumab / teriparatide are typical first-line.

    09Safety uncertainty score

    Moderate

    Safety profile partly characterised; some signals from observational or preclinical data.

    10Known adverse signals

    • EMA / MHRA cancer-risk signal restricted long-term osteoporosis use (2013).
    • Nasal irritation, flushing.
    • Antibody formation with chronic use.

    11Drug-interaction uncertainty

    Moderate

    Some interaction data published; check with a prescriber for your specific medicines.

    12Anti-doping status

    WADA: Low sport riskWADA strict-liability framing applies.

    13UK legal position

    UK: Prescription-only (UK POM)

    Available for specific indications; use restricted to short-term treatment.

    14EU legal position

    Use restricted due to cancer risk concerns; limited indications.

    15What this page cannot tell you

    • Whether off-label long-term use carries the same cancer signal as restricted indication.

    16Last reviewed

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    17Citation quality score

    AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

    18Research gaps

    • Superseded by bisphosphonates / denosumab / teriparatide for routine osteoporosis.

    19Safer alternatives / established care pathways

    • NICE TA161 / TA204 osteoporosis pathway: lifestyle + calcium / vitamin D + bisphosphonate first-line.
    • Specialist referral for severe / refractory cases.

    Related Safety Centre page → Prescription-only medicines

    20Doctor discussion prompts

    Questions to ask a qualified clinician

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • What is the appropriate UK osteoporosis treatment for my situation?

    Discovery & History

    Calcitonin was discovered independently by Harold Copp (Canada) and Paul Foster and others (UK) in 1962. Copp coined the name "calcitonin" for its calcium-lowering effects. Initially, researchers believed calcitonin came from the parathyroid glands. The thyroid origin was established later, specifically from the parafollicular or C cells of the thyroid. The discovery of calcitonin completed the understanding of calcium homeostasis: parathyroid hormone raises blood calcium; calcitonin lowers it. This led to therapeutic applications in conditions of excess bone resorption. Salmon calcitonin was found to be 40-50 times more potent than human calcitonin and more resistant to degradation. This made it preferred for therapeutic use. Synthetic salmon calcitonin (calcitonin-salmon) became available in the 1970s. Therapeutic applications developed for Paget's disease, osteoporosis, and hypercalcemia. Nasal spray formulations improved convenience for osteoporosis treatment. In 2013, the EMA recommended restricting calcitonin use due to a small but significant increased cancer risk observed with long-term use. This, combined with availability of more effective osteoporosis treatments, has reduced calcitonin's clinical role.

    Mechanism of Action

    Calcitonin acts through specific G protein-coupled receptors: **Calcitonin Receptor (CTR)** The calcitonin receptor is expressed on target cells: - Osteoclasts: Primary target for bone effects - Kidney tubules: Calcium excretion - Central nervous system: Analgesic effects **Osteoclast Inhibition** Primary mechanism for bone protection: - Rapidly inhibits osteoclast activity - Causes osteoclast contraction and cessation of resorption - Reduces release of calcium from bone - Effect is relatively short-lived (receptor desensitization) **Renal Effects** Increases urinary calcium and phosphate: - Reduces tubular reabsorption of calcium - Contributes to lowering of blood calcium **Analgesic Effects** Distinct from anti-resorptive effects: - May involve central beta-endorphin release - Useful for bone pain (Paget's, vertebral fractures) - Mechanism not fully understood **Receptor Desensitization** An important limitation: - Chronic exposure leads to receptor downregulation - Effects diminish over time - Limits long-term efficacy for osteoporosis

    Researched Benefits

    Based on preclinical and clinical research findings:

    • 1
      Rapid reduction of hypercalcemia
    • 2
      Reduction of bone turnover in Paget's disease
    • 3
      Pain relief in vertebral fractures and bone disease
    • 4
      Modest reduction in vertebral fracture risk (osteoporosis)
    • 5
      Important tumor marker for medullary thyroid cancer

    Claim vs Evidence

    How popular claims about Calcitonin stack up against the current research, graded using our public evidence grading methodology.

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Best long-term option for osteoporosis”BYesHighCalcitonin is no longer recommended for long-term osteoporosis treatment due to cancer-risk signals; bisphosphonates / denosumab / teriparatide are typical first-line.

    Theoretical Dosing & Protocols

    ⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
    Theoretical DosageVaries by indication; 200 IU nasal daily for osteoporosis; 4-8 IU/kg injection for hypercalcemia
    FrequencyDaily (nasal) or as needed (injection)
    DurationLimited duration recommended due to cancer concerns
    NotesCalcitonin use has declined due to availability of better alternatives and cancer risk concerns. It remains useful for specific situations like acute hypercalcemia and Paget's disease. Use should be time-limited.

    Administration Routes

    Routes studied in research settings (educational only):

    • Nasal spray (osteoporosis, most convenient)
    • Subcutaneous or intramuscular injection
    • Intravenous (hypercalcemia emergencies)
    Half-LifeStability
    Approximately 10-15 minutes (short)Commercial preparations stable per manufacturer specifications

    Safety Profile & Known Risks

    Commonly Reported Side Effects

    • Nasal irritation and rhinitis (nasal spray)
    • Nausea
    • Flushing
    • Injection site reactions
    • Allergic reactions (especially salmon-derived)

    Rare Risks & Concerns

    • Increased cancer risk with long-term use
    • Serious allergic/anaphylactic reactions
    • Hypocalcemia (excessive effect)

    Contraindications

    • Known hypersensitivity to calcitonin
    • Hypocalcemia
    • Long-term use discouraged

    UK & EU Regulatory Context

    🇬🇧 United Kingdom

    Available for specific indications; use restricted to short-term treatment.

    🇪🇺 European Union

    Use restricted due to cancer risk concerns; limited indications.

    Calcitonin use has been restricted in many jurisdictions following EMA recommendations in 2013. Long-term use for osteoporosis is no longer recommended. Short-term use for hypercalcemia and Paget's disease remains appropriate.

    Clinical Studies Summary

    Neurophysiological Effects of Dry Needling: A Systematic Review and Meta-analysis.

    The application of dry needling can induce significant changes in pain-related biomarker levels in animal and human studies, providing insights into its underlying mechanisms of action and potential clinical effects.

    Arch Phys Med Rehabil. 2026View on PubMed

    Safety and efficacy of calcitonin gene-related peptide antagonists for cluster headache: a systematic review and meta-analysis.

    Calcitonin gene-related peptide antagonists provide preventive benefit with acceptable safety in cluster headache. These findings should be interpreted as supportive but less definitive. Larger, long-term, placebo-controlled randomized trials are needed to confirm efficacy and guide clinical use.

    BMC Neurol. 2026View on PubMed

    Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis.

    Tirzepatide use in RCTs over 26 to 72 weeks did not increase overall or specific cancer risk.

    Endocrinol Metab (Seoul). 2025View on PubMed

    Comparative Effectiveness of Pharmacologic Treatments for the Prevention of Episodic Migraine Headache: A Systematic Review and Network Meta-analysis for the American College of Physicians.

    No high-certainty evidence favored one pharmacologic treatment for prevention of episodic migraine over another. Evidence was mostly insufficient or of low certainty.

    Ann Intern Med. 2025View on PubMed

    Network meta-analysis comparing efficacy of different strategies on medication-overuse headache.

    Combination therapies, including anti-CGRP(R) therapies and nerve blocks, appear to be the most effective strategies for MOH management, highlighting their potential as initial treatment options. While headache prevention strategies demonstrated similar efficacy, abrupt withdrawal alone was insufficient.

    J Headache Pain. 2025View on PubMed

    PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.

    R. declares that he has received consulting fees or has been on paid advisory boards for IBSA-Genevrier, Viatris, Radius Health, Rejuvenate Biomed, Celltrion, Promedius, and Theramex; received lecture fees when speaking at the invitation of the sponsor for IBSA-Genevrier, Theramex, and Viatris; and received grant support from IBSA-Genevrier, Viatris, Radius Health, and TRB, all through institutions and outside the su…

    Osteoporos Int. 2025View on PubMed

    Registered Trials & Regulatory Status

    Registered trials
    44
    Currently recruiting
    4
    Furthest phase
    Phase 4
    Approved product
    Yes
    CALCITONIN SALMON, OSTEOBIOS

    22 of 29 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

    Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness

    PHASE4

    Status: Not Yet Recruiting · 30 participants · Insel Gruppe AG, University Hospital Bern

    Conditions: Acute Mountain Sickness

    No results postedNCT07653516

    Adding Calcitonin to Bupivacaine in Transversalis Fascia Plane Block for Cesarean Section

    NA

    Status: Recruiting · 70 participants · Tanta University

    Conditions: Transversalis Fascia Plane Block

    No results postedNCT07033104

    Paravertebral Calcitonin in Thoracotomy

    NA

    Status: Completed · 92 participants · Tanta University

    Conditions: Calcitonin, Paravertebral, Thoracotomy

    No results postedNCT06330168

    Evaluation of the Levels of Calcitonin Gene-related Peptide and Substance P

    N/A

    Status: Recruiting · 51 participants · Melike Cengiz

    Conditions: Meningitis, Diagnosis, Prognosis

    No results postedNCT06510751

    Ultrasound Guided Block of Stellate Ganglion Versus Greater Occipital Nerve in Resistant Migraine and Correlation to Calcitonin Gene Related Peptide

    NA

    Status: Recruiting · 40 participants · Ain Shams University

    Conditions: Migraine

    No results postedNCT06662461

    Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia

    N/A

    Status: Completed · 103 participants · Nvision Laser Eye Centers

    Conditions: Dry Eye, Asthenopia

    No results postedNCT05895500

    Stimulation-evoked Calcitonin Gene-Related Peptide (CGRP) as Biomarker of Migraine

    N/A

    Status: Unknown · 20 participants · University Medicine Greifswald

    Conditions: Migraine

    No results postedNCT05768828

    The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients

    PHASE3

    Status: Completed · 200 participants · Kafrelsheikh University

    Conditions: Effect of Drug, Migraine Disorders

    No results postedNCT05632133

    Calcitonin Level and New-onset of Post-Operative Atrial Fibrillation

    N/A

    Status: Unknown · 200 participants · Tongji Hospital

    Conditions: Calcitonin Secretion Disorder, Post-operative Atrial Fibrillation

    No results postedNCT04993456

    Efficacy of Coadministration of Calcitonin and Hyperbaric Bupivacaine in Spinal Anesthesia in Tramadol-abuse Patients

    PHASE4

    Status: Completed · 90 participants · Ain Shams University

    Conditions: Analgesia

    No results postedNCT04445857

    The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients

    NA

    Status: Unknown · 72 participants · Danish Headache Center

    Conditions: Migraine, Migraine Without Aura, Migraine With Aura

    No results postedNCT04452929

    The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries

    PHASE4

    Status: Completed · 21 participants · University of Missouri-Columbia

    Conditions: Pelvic Ring Fractures

    Results postedNCT03812991

    Adverse event reports (FDA FAERS)

    • drug ineffective448
    • nausea205
    • off label use193
    • fatigue178
    • death150
    • hypercalcaemia150
    • fall144
    • diarrhoea136
    • pain133
    • vomiting128

    FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.

    Source: ClinicalTrials.gov and openFDA. Updated automatically.

    Looking for Calcitonin?

    Source research-grade Calcitonin from a trusted UK supplier — third-party tested with certificate of analysis.

    View at Supplier

    Frequently Asked Questions

    Questions to ask a qualified clinician about Calcitonin

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • What is the appropriate UK osteoporosis treatment for my situation?

    UK regulatory & safety context

    Prescription-only medicines

    Safety Centre guide

    Related Peptides

    ACTH

    A pituitary hormone that stimulates cortisol production, used diagnostically and therapeutically for various conditions including infantile spasms.

    Learn more

    Amylin

    A pancreatic hormone co-secreted with insulin that regulates glucose and appetite, the basis for the diabetes drug pramlintide.

    Learn more

    PTH 1-34

    The biologically active fragment of parathyroid hormone approved for osteoporosis treatment, representing the first anabolic bone therapy.

    Learn more

    Explore More Peptides

    Browse our comprehensive database of research-backed peptide profiles.